Ustekinumab. Otros usos. Otras formas de psoriasis. Otras patologías cutáneas

Sánchez-Regaña, M.

doi:10.1016/S0001-7310(12)70010-8

Article information

Resumen

Ustekinumab es un anticuerpo monoclonal humano anti interleucina 12 y 23. En los ensayos clínicos pivotales quedó probada su eficacia y seguridad a nivel de la psoriasis en placas moderada-severa. Asimismo, cabe destacar que en dichos ensayos se utilizó también el índice de severidad de psoriasis ungueal para evaluar su efectividad en la psoriasis ungueal. Los pacientes tratados en el ensayo PHOENIX 1 (n=545) mostraron que las lesiones ungueales mejoraron de forma progresiva hasta la semana 52, si bien en la semana 12, después de dos dosis de ustekinumab, la mediana de la mejoría de las puntuaciones NASPI respecto al valor basal fue del 25%, llegando al 50% en la semana 24. Por otro lado, desde su reciente incorporación, ustekinumab también se ha empleado en otras formas de psoriasis (pustulosa, palmo-plantar, eritrodérmica) y también en otras enfermedades (pitiriasis rubra pilaris, hidradenitis supurativa y dermatitis atópica).

Palabras clave:

Ustekinumab

Psoriasis

Psoriasis ungueal

Pitiriasis rubra pilaris

Abstract

Ustekinumab is a human monoclonal antibody directed against IL-12 and IL-23. Pivotal clinical trials have proven its efficacy and safety in the treatment of moderate to severe plaque psoriasis. The same trials have also evaluated the efficacy of this drug in nail psoriasis using the Nail Psoriasis Severity Index (NAPSI). Patients treated in the PHOENIX 1 trial (n=545) showed progressive improvement in NAPSI scores up to week 52. At week 12, after 2 doses of ustekinumab, the median improvement from baseline was 25% and at week 24, it was 50%. Since its recent approval for the treatment of moderate to severe plaque psoriasis, ustekinumab has been used to treat other forms of psoriasis (pustular, palmoplantar, and erythrodermic psoriasis) and other diseases (pityriasis rubra pilaris, hidradenitis suppurativa, and atopic dermatitis).

Keywords:

Ustekinumab

Psoriasis

Nail psoriasis

Pityriasis rubra pilaris

Full text is only aviable in PDF

Bibliografía

[1.]

M. Sánchez-Regaña, P. Umbert.

Aspectos diagnósticos y terapéuticos de la psoriasis ungueal.

Actas Dermosifiliogr, 99 (2008), pp. 34-43

Medline

[2.]

S. Armesto, A. Esteve, P. Coto-Segura, M. Drake, C. Galache, J. Martínez-Borra, et al.

Psoriasis ungueal: estudio en 661 pacientes con psoriasis vulgar.

Actas Dermosifiliogr, 102 (2011), pp. 365-372

http://dx.doi.org/10.1016/j.ad.2011.02.007 | Medline

[3.]

M. Sánchez-Regaña, J. Sola-Ortigosa, M. Alsina-Gibert, M. Vidal-Fernández, P. Umbert-Millet.

Nail psoriasis: a retrospective study on the effectiveness of systemic treatments (classical and biological therapy).

J Eur Acad Dermatol Venereol, 25 (2011), pp. 579-586

http://dx.doi.org/10.1111/j.1468-3083.2010.03938.x | Medline

[4.]

M. Augustin, K. Reich, C. Blome, I. Schäfer, A. Laass, M.A. Radtke.

Nail psoriasis in Germany: epidemiology and burden of disease.

Br J Dermatol, 163 (2010), pp. 580-585

http://dx.doi.org/10.1111/j.1365-2133.2010.09831.x | Medline

[5.]

D. McGonagle, A.L. Tan, M. Benjamin.

The nail as a musculoskeletal appendage-implications for an improved understanding of the link between psoriasis and arthritis.

Dermatology, 218 (2009), pp. 97-102

http://dx.doi.org/10.1159/000182250 | Medline

[6.]

E.M. De Jong, B.A. Seegers, M.K. Gulinck, J.B. Boezeman, P.C. Van de Kerkhof.

Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1.728 patients.

Dermatology, 193 (1996), pp. 300-303

Medline

[7.]

R. Langley, E. Daudén.

Treatment and management of psoriasis with nail involvement: a focus on biologic therapy.

Dermatology, 221 (2010), pp. 29-42

http://dx.doi.org/10.1159/000316179 | Medline

[8.]

M. Sánchez-Regaña, S. Videla, J. Villoria, H. Domingo, A. Macaya, E. Ortiz, et al.

Prevalence of fungal involvement in a series of patients with nail psoriasis.

Clin Exp Dermatol, 33 (2008), pp. 194-195

http://dx.doi.org/10.1111/j.1365-2230.2007.02568.x | Medline

[9.]

A. Tosti, C. Ricotti, P. Romanelli, N. Cameli, B.M. Piraccini.

Evaluation of the efficacy of acitretin therapy for nail psoriasis.

Arch Dermatol, 145 (2009), pp. 269-271

http://dx.doi.org/10.1001/archdermatol.2008.600 | Medline

[10.]

T. Syuto, M. Abe, H. Ishibuchi, O. Ishikawa.

Successful treatment of psoriatic nails with low-dose cyclosporine administration.

Eur J Dermatol, 17 (2007), pp. 248-249

http://dx.doi.org/10.1684/ejd.2007.0162 | Medline

[11.]

P. Rich, C.E. Griffiths, K. Reich, F.O. Nestle, R.K. Scher, S. Li, et al.

Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year.

J Am Acad Dermatol, 58 (2008), pp. 224-231

http://dx.doi.org/10.1016/j.jaad.2007.07.042 | Medline

[12.]

C.L. Leonardi, A.B. Kimball, K.A. Papp, N. Yeilding, C. Guzzo, Y. Wang, et al.

PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 1).

Lancet, 371 (2008), pp. 1665-1674

http://dx.doi.org/10.1016/S0140-6736(08)60725-4 | Medline

[13.]

F. Van den Bosch, B. Manger, P. Goupille, N. McHugh, E. Rødevand, P. Holck, et al.

Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions.

Ann Rheum Dis, 69 (2010), pp. 394-399

http://dx.doi.org/10.1136/ard.2009.111856 | Medline

[14.]

T.A. Luger, J. Barker, J. Lambert, S. Yang, D. Robertson, J. Foehl, et al.

Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis.

J Eur Acad Dermatol Venereol, 23 (2009), pp. 896-904

http://dx.doi.org/10.1111/j.1468-3083.2009.03211.x | Medline

[15.]

C. Budai Livideanu, M. Lahfa, J. Mazereeuw-Hautier, C. Paul.

Efficacy of ustekinumab in palmoplantar psoriasis.

Dermatology, 221 (2010), pp. 321-323

http://dx.doi.org/10.1159/000320961 | Medline

[16.]

J. Santos-Juanes, P. Coto-Segura, A. Mas-Vidal, C. Galache-Osuna.

Ustekinumab induces rapid clearing of erythrodermic psoriasis after failure of antitumor necrosis factor therapies.

Br J Dermatol, 162 (2010), pp. 1144-1146

http://dx.doi.org/10.1111/j.1365-2133.2010.09669.x | Medline

[17.]

E. Daudén, D. Santiago-et-Sánchez-Mateos, E. Sotomayor-López, A. García-Díez.

Ustekinumab: effective in a patient with severe recalcitrant generalized pustular psoriasis.

Br J Dermatol, 163 (2010), pp. 1346-1347

http://dx.doi.org/10.1111/j.1365-2133.2010.09995.x | Medline

[18.]

N. Merino de Paz, M. Rodríguez, P. Contreras, M. Pestaña, A. Noda, M. García.

Resolución de un brote de psoriasis pustulosa con ustekinumab en una paciente de difícil control.

Piel (Barc), (2011),

[19.]

K.S. Wenk, J.M. Claros, A. Ehrlich.

Flare of pustular psoriasis after initiating ustekinumab therapy.

J Dermatolog Treat, (2011),

[20.]

S. Gregoriou, C. Kazakos, E. Christofidou, G. Kontochristopoulos, G. Vakis, D. Rigopoulos.

Pustular psoriasis development after initial ustekinumab administration in chronic plaque psoriasis.

Eur J Dermatol, 21 (2011), pp. 104-105

http://dx.doi.org/10.1684/ejd.2011.1164 | Medline

[21.]

J.M. Ko, A.B. Gottlieb, J.F. Kerbleski.

Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases.

J Dermatolog Treat, 20 (2009), pp. 100-108

http://dx.doi.org/10.1080/09546630802441234 | Medline

[22.]

S. Gerdes, J. Franke, S. Domm, U. Mrowietz.

Ustekinumab in the treatment of palmoplantar pustulosis.

Br J Dermatol, 163 (2010), pp. 1116-1118

http://dx.doi.org/10.1111/j.1365-2133.2010.09897.x | Medline

[23.]

B. De Unamuno-Bustos, R. Ballester-Sánchez, V. Oliver-Martínez, V. Alegre de Miguel.

Tratamiento de la pustulosis palmo-plantar con ustekinumab.

Actas Dermosifiliogr, 102 (2011), pp. 833-835

http://dx.doi.org/10.1016/j.ad.2011.03.026 | Medline

[24.]

F. Allegue, J. Pardo, J. Ruffin, E. Abbad, A. López, J. Pereda, et al.

Treatment of acrodermatitis continua of Hallopeau with ustekinumab.

J Eur Acad Dermatol, 24 (2010), pp. 30-31

[25.]

R. Ruiz-Villaverde, D. Sánchez-Cano.

Successful treatment of type 1 pityriasis rubra pilaris with ustekinumab therapy.

Eur J Dermatol, 20 (2010), pp. 630-631

http://dx.doi.org/10.1684/ejd.2010.1004 | Medline

[26.]

J. Wohlrab, B. Kreft.

Treatment of pityriasis rubra pilaris with ustekinumab.

Br J Dermatol, 163 (2010), pp. 655-656

http://dx.doi.org/10.1111/j.1365-2133.2010.09855.x | Medline

[27.]

A. Grant, T. González, M.O. Montgomery, V. Cárdenas, F.A. Kerdel.

Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebocontrolled crossover trial.

J Am Acad Dermatol, 62 (2010), pp. 205-217

http://dx.doi.org/10.1016/j.jaad.2009.06.050 | Medline

[28.]

R. Blanco, V.M. Martínez-Taboada, I. Villa, M.C. González-Vela, H. Fernández-Llaca, M. Agudo, et al.

Long-term successful adalimumab therapy in severe hidradenitis suppurativa.

Arch Dermatol, 145 (2009), pp. 580-584

http://dx.doi.org/10.1001/archdermatol.2009.49 | Medline

[29.]

W.P. Gulliver, G.B. Jemec, K.A. Baker.

Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa.

J Eur Acad Dermatol Venereol, (2011),

[30.]

V.R. Sharon, M.S. García, S. Bagheri, H. Goodarzi, C. Yang, Y. Ono, et al.

Management of recalcitrant hidradenitis suppurativa with ustekinumab.

Acta Derm Venereol, (2011),

[31.]

Fernández-Antón MC, Mendoza MD, Cieza D, Longo MI, Suárez R. Ustekinumb en el tratamiento de la dermatitis atópica severa. Nuestra experiencia en 4 pacientes. Proceedings of the 39 Congreso Nacional de la Academia Española de Dermatología y Venereología. Santiago de Compostela, 8–11 Jun 2011.

[32.]

R. Puya, Alvarez-López, A. Velez, E. Casas Asunción, J.C. Moreno.

Treatment of severe refractory adult atopic dermatitis with ustekinumab.

Int J Dermatol, 51 (2012), pp. 115-116

http://dx.doi.org/10.1111/j.1365-4632.2011.05195.x | Medline

Indexed in:

Follow us:

Indexed in:

Follow us:

Subscribe to our newsletter